Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico

References

• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–309.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. The Lancet Infectious Diseases; 2018.
   Google Scholar
• Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling MJ, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. The Lancet Global Health. 2017;5(1):e51–e59. doi:10.1016/S2214-109X(16)30306-0.
   PubMed Web of Science ®Google Scholar
• Gutiérrez JP R-DJ, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, and H.-Á.M. Romero-Martínez M. ENSANUT2012 resultados nacionales.pdf. Editor, 2012 ed.: Instituto Nacional de Salud Pública; 2012.
   Google Scholar
• Carnalla-Barajas MN, Soto-Noguerón A, Sánchez-Alemán MA, Solórzano-Santos F, Velazquez-Meza ME, Echániz-Aviles G, et al. Changing trends in serotypes of S. pneumoniae isolates causing invasive and non-invasive diseases in unvaccinated population in Mexico (2000-2014). Int J Infect Dis. 2017;58:1–7. doi:10.1016/j.ijid.2017.02.005.
   PubMed Web of Science ®Google Scholar
• Palacios MG, Cané AG,A, Curcio D. Changes In Childhood Meningitis, Pneumonia And Acute Otitis Media After Universal Vaccination With Pneumococcal Conjugate Vaccines In Mexico (2004-2014). In: International Society of Pneumococci and Pneumococcal Diseases. Scotland: Glasgow; 2016.
   Google Scholar
• Epidemiología DGD Anuario de Morbilidad 1984-2016. 1984-2016. 2017. Available From: http://www.epidemiologia.salud.gob.mx/anuario/html/anuarios.html.
   Google Scholar
• Mucino-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines]. Value Health. 2011;14(5 Suppl 1):S65–70. doi:10.1016/j.jval.2011.05.025.
   PubMedGoogle Scholar
• Gómez JA, Villaseñor-Sierra A, Aguilar GM, Manjarrez RC, Cervantes-Apolinar MY. Estimación de la relación costo-efectividad de las vacunas neumocócicas conjugadas Prevenar-13 y Synflorix®, utilizadas en los programas de vacunación de población infantil Mexicana. Value in Health Regional Issues. 2016;11:76–84. doi:10.1016/j.vhri.2016.07.009.
   PubMedGoogle Scholar
• Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert R-R, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Rev Vaccines. 2017;16(10):1007–1027. doi:10.1080/14760584.2017.1362339.
   PubMed Web of Science ®Google Scholar
• Desmet S, Verhaegen J, Van Ranst M, Peetermans W, Lagrou K. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach?. Lancet Infect Dis. 2018. DOI:10.1016/S1473-3099(18)30346-3.
   PubMed Web of Science ®Google Scholar
• Janoir C, Lepoutre A, Gutmann L, Varon E. Insight into resistance phenotypes of emergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolated from invasive disease after 13-valent pneumococcal conjugate vaccine implementation in France. Open Forum Infect Dis. 2016;3(1):ofw020. doi:10.1093/ofid/ofw020.
   PubMed Web of Science ®Google Scholar
• Castañeda E, Agudelo CI, De Antonio R, Rosselli D, Calderón C, Ortega-Barria E, et al. Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990–2010. BMC Infect Dis. 2012;12(1):124. doi:10.1186/1471-2334-12-166.
   PubMedGoogle Scholar
• Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+ 1 infant schedule in Quebec, Canada. Pediatr Infect Dis J. 2010;29(6):546–549. doi:10.1097/INF.0b013e3181cffa2a.
   PubMed Web of Science ®Google Scholar
• Domingues CMAS, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2(6):464–471. doi:10.1016/S2213-2600(14)70060-8.
   PubMed Web of Science ®Google Scholar
• Brandileone M-CC, Almeida SC, Minamisava R, Andrade A-L. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018;36(19):2559–2566. doi:10.1016/j.vaccine.2018.04.010.
   PubMed Web of Science ®Google Scholar
• Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, et al. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018;36(15):1934–1940. doi:10.1016/j.vaccine.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657. doi:10.1371/journal.pmed.1001657.
   PubMed Web of Science ®Google Scholar
• Moffatt M, Sings H, Hilton B, Wasserman M, Farkouh R, editors. A review of higher-valent pneumococcal conjugate vaccine (PCV) impact on acute otitis media (AOM) and nasopharyngeal carriage (NPC) due to nontypeable haemophilus influenzae (NTHI). In: European Society for Paediatric Infectious Diseases (ESPID) 2017; Madrid (Spain): ESPID. p. 23-27.
   Google Scholar
• Wasserman M, Sings HL, Jones D, Pugh S, Moffatt M, Farkouh R. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Rev Vaccines. 2018;17(1):71–78. doi:10.1080/14760584.2018.1409116.
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children–a population-based study. PLoS One. 2015;10(3):e0120290. doi:10.1371/journal.pone.0120290.
   PubMed Web of Science ®Google Scholar
• Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, Baquero F, Hernández-Sampelayo T, et al. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015. PloS One. 2017;12(2):e0172222. doi:10.1371/journal.pone.0172222.
   PubMed Web of Science ®Google Scholar
• Tagarro A, Benito A, Sanchez A, Aznar E, Otheo E, Sanz-Rosa D, et al. Bacteremic pneumonia before and after withdrawal of 13-valent pneumococcal conjugate vaccine from a public vaccination program in spain: a case-control study. J Pediatr. 2016;171:111–115. e1-3. doi:10.1016/j.jpeds.2015.12.031.
   PubMed Web of Science ®Google Scholar
• Organización Panamericana de la Salud O. Informe Regional SIREVA II 2011: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores. Washington DC: Organización Panamericana de la Salud, OMS, 2011. Available at: https://www.insp.mx/lineas-de-investigacion/medicamentos-en-salud-publica/sireva.html
   Google Scholar
• Organización Panamericana de la Salud O. Informe Regional SIREVA II 2012: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores. Washington DC: 2012. Available at: https://www.insp.mx/lineas-de-investigacion/medicamentos-en-salud-publica/sireva.html
   Google Scholar
• Instituto Nacional de Salud Pública SdS. Reporte de serotipos y susceptibilidad antimicrobiana de S. pneumoniae y H. influenzae. Cuernavaca, Morelos: Secretaría de Salud, 2013. Available at: https://www.insp.mx/lineas-de-investigacion/medicamentos-en-salud-publica/sireva.html
   Google Scholar
• Instituto Nacional de Salud Pública SdS. Reporte de serotipos y susceptibilidad antimicrobiana de S. pneumoniae y H. influenzae. Cuernavaca, Morelos: Secretaría de Salud, 2014. Available at: https://www.insp.mx/lineas-de-investigacion/medicamentos-en-salud-publica/sireva.html
   Google Scholar
• Instituto Nacional de Salud Pública SdS. Reporte de serotipos y susceptibilidad antimicrobiana de S. pneumoniae, H. influenzae y S. aureus. Cuernavaca, Morelos, México: Secretaría de Salud, 2015 Contract No.: 2015. Available at: https://www.insp.mx/lineas-de-investigacion/medicamentos-en-salud-publica/sireva.html
   Google Scholar
• Wilson M, Wasserman M, Jadavi T, Postma M, Breton M-C, Peloquin F, et al. Clinical and Economic Impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infectious Diseases and Therapy; Chester (United Kingdom), 2018.
   Google Scholar
• van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30(50):7205–7213. doi:10.1016/j.vaccine.2012.10.017.
   PubMed Web of Science ®Google Scholar
• Thorrington D, van Rossum L, Knol M, de Melker H, Rümke H, Hak E, et al. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PloS One. 2018;13(2):e0192640. doi:10.1371/journal.pone.0192640.
   PubMed Web of Science ®Google Scholar
• Thorrington D, Andrews N, Stowe J, Miller E, van Hoek AJ. Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. BMC Med. 2018;16(1):13. doi:10.1186/s12916-018-1004-z.
   PubMedGoogle Scholar
• Lewnard JA, Givon-Lavi N, Weinberger DM, Lipsitch M, Dagan R. Pan-serotype reduction in progression of Streptococcus pneumoniae to otitis media after rollout of pneumococcal conjugate vaccines. Clin Infect Dis. 2017;65(11):1853–1861. doi:10.1093/cid/cix673.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin Infect Dis. 2016;63(5):611–618. doi:10.1093/cid/ciw347.
   PubMed Web of Science ®Google Scholar
• Lau WC, Murray M, El-Turki A, Saxena S, Ladhani S, Long P, et al. Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom. Vaccine. 2015;33(39):5072–5079. doi:10.1016/j.vaccine.2015.08.022.
   PubMed Web of Science ®Google Scholar
• Sigurdsson S, Eythorsson E, Hrafnkelsson B, Erlendsdóttir H, Kristinsson KG, Haraldsson Á. Reduction in all-cause acute otitis media in children< 3 years of age in primary care following vaccination with 10-valent pneumococcal haemophilus influenzae protein-d conjugate vaccine: a whole-population study. Oxford (UK): Clinical Infectious Diseases. 2018. p. ciy233.
   Google Scholar
• Griffin MR, Mitchel E, Moore MR, Whitney CG, Grijalva CG, Centers for Disease C, et al. Declines in pneumonia hospitalizations of children aged &lt;2 years associated with the use of pneumococcal conjugate vaccines - Tennessee, 1998-2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):995–998.
   PubMed Web of Science ®Google Scholar
• Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceno R, et al. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014;33(6):637–642.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Deceuninck G, Lefebvre B, De Wals P. Forecasting trends in invasive pneumococcal disease among elderly adults in Quebec. Can J Infect Dis Med Microbiol. 2017;2017.
   Web of Science ®Google Scholar
• CONAPO. Consejo nacional de población: 2004-2014. Available from: https://www.gob.mx/conapo.
   Google Scholar
• Instituto Nacional de Estadísticas Geografía e Informática [INEGI] (1986). Estadísticas Históricas de México Tomo I.: http://www.beta.inegi.org.mx/app/biblioteca/ficha.html?upc=702825460238, p. 145
   Google Scholar
• Buzzo AR, Roberts C, Mollinedo LG, Quevedo JM, Casas GL, Soldevilla JMS. Morbidity and mortality of pneumonia in adults in six Latin American countries. Int J Infect Dis. 2013;17(9). e673-e677 doi:10.1016/j.ijid.2013.02.015.
   PubMed Web of Science ®Google Scholar
• Valenzuela MT, O'Loughlin R, De La Hoz F, Gomez E, Constenla D, Sinha A, et al. The burden of pneumococcal disease among Latin American and Caribbean children: review of the evidence. Revista Panamericana De Salud Pública. 2009;25:270–279.
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, et al. Bacterial meningitis in the United States, 1998–2007. New England J Med. 2011;364(21):2016–2025. doi:10.1056/NEJMoa1005384.
   PubMed Web of Science ®Google Scholar
• Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. Jama. 2008;299(17):2048–2055. doi:10.1001/jama.299.17.2048.
   PubMed Web of Science ®Google Scholar
• Mclntyre PB, Berkey CS, King SM, Schaad UB, Kilpi T, Kanra GY, et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since 1988. Jama. 1997;278(11):925–931.
   PubMed Web of Science ®Google Scholar
• Morrow A, De Wals P, Petit G, Guay M, Erickson LJ. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol. 2007;18(2):121–127.
   PubMed Web of Science ®Google Scholar
• Organization PAH. Expanded program of immunization vaccine prices for year 2017. Washington DC (USA): Pan American Health Organization; 2017.
   Google Scholar
• Arroyave Loaiza María Gilma, Aburto Mejía Rocío. Grupos Relacionados con el Diagnóstico: Producto Hospitalario. GRD-IMSS: 2014. ISBN: 978-607-9464-50-9.
   Google Scholar
• SNTSS. Sindicato nacional de trabajadores del seguro social. 2017; Available from: http://www.sntss.org.mx/phocadownload/Comunicados/tabulador.pdf.
   Google Scholar
• Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15(4):369–376.
   PubMed Web of Science ®Google Scholar
• Bennett JE, Sumner W, Downs SM, Jaffe DM. Parents’ utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154(1):43–48.
   PubMedGoogle Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–4214. doi:10.1016/j.vaccine.2004.05.003.
   PubMed Web of Science ®Google Scholar
• Knol MJ, Berbers GA, Bootsma H, van der Ende A, Kaaijk P, Rots N, et al. 7.9 Pneumococcal disease. In: The national immunisation programme in the netherlands surveillance and developments in 2015-2016. 2016. cited 2017 26 February RIVM Report 2016-0141:[Available from http://www.rivm.nl/bibliotheek/rapporten/2016-0141.pdf.
   Google Scholar
• Knol MJ, de Melker HE, Sanders EAM, van der Ende A, editors. Incidence of IPD in the Netherlands up to five years after introduction of PCV10. Bilthoven (Netherlands): National Institute for Public Health and the Environment; 2016.
   Google Scholar
• National Institute for Health and Welfare Incidence of invasive pneumococcal disease in Finland. 2016 2016 Jun 23; Available from: https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/projects-and-programmes/monitoring-the-population-effectiveness-of-pneumococcal-conjugate-vaccination-in-the-finnish-national-vaccination-programme/incidence-of-invasive-pneumococcal-disease-in-finland.
   Google Scholar